Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

समान संसाधन

• Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
  द्वारा: Magnenat, Laurent, और अन्य
  प्रकाशित: (2016)
• Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
  द्वारा: Hillson, Jan, और अन्य
  प्रकाशित: (2018)
• Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
  द्वारा: Puri, Adeep, और अन्य
  प्रकाशित: (2017)
• AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
  द्वारा: Hercogová, J., और अन्य
  प्रकाशित: (2019)
• Force Degradation Comparative Study on Biosimilar Adalimumab and Humira
  द्वारा: Aida Badamchi Shabestari, और अन्य
  प्रकाशित: (2018)